Tags

Type your tag names separated by a space and hit enter

The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
J Am Acad Dermatol. 2003 Jul; 49(1):79-82.JA

Abstract

BACKGROUND

It was discovered that Skin Cap (Cheminova Internacional S.A., Madrid, Spain), an over-the-counter psoriasis therapy with zinc pyrithione, contained clobetasol propionate and it was withdrawn from the market by the US Food and Drug Administration review. Some suggested that there might be a synergistic effect of zinc pyrithione with clobetasol propionate.

OBJECTIVE

We sought to evaluate the efficacy of clobetasol propionate 0.05% foam with and without the coadministration of a topical 0.25% zinc pyrithione spray in treating psoriasis involving sites other than the scalp.

METHODS

We conducted a randomized, double-blind, right/left study of patients with mild to moderate, generally symmetric, plaque-type psoriasis. Patients were assigned to treatment with clobetasol propionate foam on all psoriatic lesions and then randomly assigned to use zinc pyrithione spray to either the right or left side of their body (vehicle spray to be applied to the opposite side). There was a 2-week treatment phase (visits at baseline, week 1, and week 2) and a follow-up phase (visit at week 4), and all treatments were administered twice daily for 2 weeks. The primary outcome measure was the change from baseline to week 2 in the composite score of the signs of psoriasis (erythema, scaling, plaque thickness) for symmetric target lesions.

RESULTS

A total of 25 patients were enrolled; 24 completed the trial and 1 was lost to follow up. Of those who completed the study, 63% (15 of 24) were men, and the mean age (+/-SD) was 50 years (+/-12.2). After 2 weeks of therapy, the average decline in the composite score was 3.5 (+/-1.8) for monotherapy (clobetasol propionate foam and vehicle) and, similarly, 3.3 (+/-1.8) for clobetasol propionate foam plus zinc pyrithione spray (P =.5).

DISCUSSION

Zinc pyrithione spray does not appear to enhance the efficacy of clobetasol propionate foam after 2 weeks of therapy.

Authors+Show Affiliations

Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12833013

Citation

Housman, Tamara Salam, et al. "The Use of 0.25% Zinc Pyrithione Spray Does Not Enhance the Efficacy of Clobetasol Propionate 0.05% Foam in the Treatment of Psoriasis." Journal of the American Academy of Dermatology, vol. 49, no. 1, 2003, pp. 79-82.
Housman TS, Keil KA, Mellen BG, et al. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol. 2003;49(1):79-82.
Housman, T. S., Keil, K. A., Mellen, B. G., McCarty, M. A., Fleischer, A. B., & Feldman, S. R. (2003). The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. Journal of the American Academy of Dermatology, 49(1), 79-82.
Housman TS, et al. The Use of 0.25% Zinc Pyrithione Spray Does Not Enhance the Efficacy of Clobetasol Propionate 0.05% Foam in the Treatment of Psoriasis. J Am Acad Dermatol. 2003;49(1):79-82. PubMed PMID: 12833013.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. AU - Housman,Tamara Salam, AU - Keil,Kimberly A, AU - Mellen,Beverly G, AU - McCarty,Martha A, AU - Fleischer,Alan B,Jr AU - Feldman,Steven R, PY - 2003/7/2/pubmed PY - 2003/8/2/medline PY - 2003/7/2/entrez SP - 79 EP - 82 JF - Journal of the American Academy of Dermatology JO - J. Am. Acad. Dermatol. VL - 49 IS - 1 N2 - BACKGROUND: It was discovered that Skin Cap (Cheminova Internacional S.A., Madrid, Spain), an over-the-counter psoriasis therapy with zinc pyrithione, contained clobetasol propionate and it was withdrawn from the market by the US Food and Drug Administration review. Some suggested that there might be a synergistic effect of zinc pyrithione with clobetasol propionate. OBJECTIVE: We sought to evaluate the efficacy of clobetasol propionate 0.05% foam with and without the coadministration of a topical 0.25% zinc pyrithione spray in treating psoriasis involving sites other than the scalp. METHODS: We conducted a randomized, double-blind, right/left study of patients with mild to moderate, generally symmetric, plaque-type psoriasis. Patients were assigned to treatment with clobetasol propionate foam on all psoriatic lesions and then randomly assigned to use zinc pyrithione spray to either the right or left side of their body (vehicle spray to be applied to the opposite side). There was a 2-week treatment phase (visits at baseline, week 1, and week 2) and a follow-up phase (visit at week 4), and all treatments were administered twice daily for 2 weeks. The primary outcome measure was the change from baseline to week 2 in the composite score of the signs of psoriasis (erythema, scaling, plaque thickness) for symmetric target lesions. RESULTS: A total of 25 patients were enrolled; 24 completed the trial and 1 was lost to follow up. Of those who completed the study, 63% (15 of 24) were men, and the mean age (+/-SD) was 50 years (+/-12.2). After 2 weeks of therapy, the average decline in the composite score was 3.5 (+/-1.8) for monotherapy (clobetasol propionate foam and vehicle) and, similarly, 3.3 (+/-1.8) for clobetasol propionate foam plus zinc pyrithione spray (P =.5). DISCUSSION: Zinc pyrithione spray does not appear to enhance the efficacy of clobetasol propionate foam after 2 weeks of therapy. SN - 0190-9622 UR - https://www.unboundmedicine.com/medline/citation/12833013/The_use_of_0_25_zinc_pyrithione_spray_does_not_enhance_the_efficacy_of_clobetasol_propionate_0_05_foam_in_the_treatment_of_psoriasis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190962203007734 DB - PRIME DP - Unbound Medicine ER -